

TABLE 1. PCR primers for amplification of the promoter region and whole coding region of the human 5-HT_{1A} receptor gene

Primer Name	Primer sequence	Primer Position	PCR product (bp)	Annealing temperature
5HT1A-AF 5HT1A-AR	5'-GGAGTAGTTGGAATTCCTCC 5'-TGTGAGTCGCTTCGAAAGCGA	-855~-835 -573~-593	283	60°C
5HT1A-BF 5HT1A-BR	5'-CAGAGGAAAGAGGCACTCCTC 5'-CCCCTAGCAAACAGTCTCCA	-664~-644 -354~-374	311	61°C
5HT1A-CF 5HT1A-CR	5'-GCTTCTCGGTTCTAGATATTTTC 5'-AGTTCTTACTGCTTCGGCGAA	-402~-381 -134~-154	269	60°C
5HT1A-DF 5HT1A-DR	5'-AAAGCTGCTCCTCGGAGATAC 5'-TGGTGATGTGGTGTGTTGCC	-177~-157 45~25	222	66°C
5HT1A-EF 5HT1A-ER	5'-ATGGATGTGCTCAGCCCTGGT 5'-ATTGGCCACGTTCTGCAGGGA	1~21 216~196	216	64°C
5HT1A-FF 5HT1A-FR	5'-TCCCTGCAGAACGTGGCCAAT 5'-GTAGTCGATGGGGTCCGTGAT	196~216 432~412	237	55°C
5HT1A-GF 5HT1A-GR	5'-ATCTTGCACCTGTGCGCCATC 5'-CCCATAGAGAACCAGCATGAG	370~390 645~625	276	58°C
5HT1A-HF 5HT1A-HR	5'-GGAGCTTTCTACATCCCGCTG 5'-CTCTTTGGAGTTGCCCACTCG	601~621 906~886	306	62°C
5HT1A-IF 5HT1A-IR	5'-CTGGAGGTGATCGAGGTGCAC 5'-GGGCAGCCAGCAGAGGATGAA	865~885 1077~1057	213	64°C
5HT1A-JF 5HT1A-JR	5'-GGAAAAATGAGCGCAACGCCG 5'-ACGGATCCTGTAGCCTCGACT	965~985 1307~1287	343	55°C

TABLE 2. PCR primers for amplification of the promoter region and whole coding region of the human AP-2 gene

Primer name	Primer sequence	Primer position	Region	PCR product (bp)	Annealing temperature
AP2PUF AP2PUR	5'-GAATTGTGCTCAGTTCAGGTAG 5'-TCATCTGGGGCTTGTTTCTCG	-1959 ~ -1938 -1633 ~ -1653	promoter	327	58°C
AP2PMF AP2PMR	5'-CACCCAGGAAACCTTAGCCTG 5'-AGACCGGCGAAGTCACTCCAG	-1052 ~ -1032 -740 ~ -760	promoter	313	66°C
AP2PO-PF AP2PO-PR	5'-CAGCTCGGATCGTGGTAGCAG 5'-CTCTCTACGCCGCGAACTTGC	-669 ~ -649 -409 ~ -429	promoter	261	58°C
AP2PD-PF AP2PD-PR	5'-GAGCTCGAGGAAGGTTTTATC 5'-GAGATCTCCCTCTAATGGTAG	-478 ~ -458 -266 ~ -286	promoter	213	58°C
AP2STRPF AP2STRPR	5'-CTACCATTAGAGGGAGATCTC 5'-CTCGTACTTGATATTATCCGTC	-286 ~ -266 36 ~ 15	promoter & partial exon 1	322	58°C
AP2STRPF AP2EX1PR	5'-CTACCATTAGAGGGAGATCTC 5'-TGACCGCACGGATGATCGAG	-286 ~ -266 80 ~ 61	exon 1	366	58°C
AP2EX2UF AP2EX2UR	5'-CAACGGGAACGGGCCATTTCC 5'-TGCAGGGGGTTCAGGCTGTAG	4438 ~ 4458 4761 ~ 4741	upper region of exon 2	324	64°C
AP2EX2DF AP2EX2DR	5'-GTCGCAAGATCCTTACTCCCAC 5'-CTGTGTTCCCTCGGCTGGTTG	4708 ~ 4729 5018 ~ 4998	down region of exon 2	311	62°C
AP2EX3PF AP2EX3PR	5'-CACTTACATCCATGTGTATC 5'-TGCCTATCTATTTGCTAATTC	8011 ~ 8030 8226 ~ 8206	exon 3	216	58°C
AP2EX4PF AP2EX4PR	5'-GACGCCCAACACGCGGCCTC 5'-GTTTCGGTTCGCCGCCACCGC	10098 ~ 10117 10445 ~ 10426	exon 4	348	71°C
AP2EX5PF AP2EX5PR	5'-GTGGTGCAGAGAACCCAATG 5'-GAAGTTCCTTCTAGTTAGCAAG	12273 ~ 12292 12484 ~ 12463	exon 5	212	58°C
AP2BEX5F AP2BEX5R	5'-CGTTACCCTGCTCACATCAC 5'-GGAGAATGTGCAGTTCCTTAAAC	12421 ~ 12440 12727 ~ 12706	AP-2B-specific region	307	58°C
AP2EX6PF AP2EX6PR	5'-CACTCTTCATTCTCTCGCAC 5'-TTTGGTTTCTCTTTCTCTTGAC	14259 ~ 14278 14509 ~ 14481	exon 6	251	58°C
AP2EX7UF AP2EX7UR	5'-CTACTAGTGCTGCCCATAGTG 5'-TGAGGTACATTTTGTCCATGGC	16041 ~ 16061 16318 ~ 16297	upper region of exon 7	278	62°C
AP2EX7DF AP2EX7DR	5'-TCACGGCCCTGCAGAACTATC 5'-GCTGATCCCGGAGCTGTCAC	16259 ~ 16279 16473 ~ 16454	down region of exon 7	215	62°C

TABLE 3. PCR primers for amplification of the promoter region in the human CREB gene

Primer name	Primer sequence	Primer position	PCR product (bp)	Annealing temperature
CREB-UF CREB-UR	5'-CCTGCTGTAGAAAACAGGCTG 5'-CGAGACTCCGCGGAAAAACC	-1034 ~ -1014 -791 ~ -810	244	66°C
CREB-MF CREB-MR	5'-TCAAGAGCAGAGCCAGGGCAG 5'-GAAGGCGAAGGCGGGCTGAG	-602 ~ -582 -365 ~ -384	238	66°C
CREB-DF CREB-DR	5'-GTCGCCC GAAGAAACCGAAG 5'-GTACAAGCTCCTCCGTCCTG	-340 ~ -320 -14 ~ -34	327	62°C

TABLE 4. Detection of DNA sequence variants in the human 5HT_{1A} receptor gene

	Variant name	Nucleotide change	Primer Pair	Gel condition for SSCP analysis	Restriction enzyme	References
Promoter region	-581C→A	-581C→A	HT1A-BF HT1A-BR	7% PAG (49:1, A:B ratio) 10% glycerol	<i>MboII</i>	present study
	-480delA	-480delA	HT1A-BF HT1A-BR	7% PAG (49:1, A:B ratio) 10% glycerol	not available	present study
	-321G→C	-321G→C	HT1A-CF HT1A-CR	10% PAG (99:1, A:B ratio)	<i>NlaIV</i>	present study
	-152C→G	-152C→G	HT1A-DF HT1A-DR	10% PAG (99:1, A:B ratio)	<i>HaeIII</i>	present study
	-51T→C	-51T→C	HT1A-DF HT1A-DR	10% PAG (99:1, A:B ratio)	<i>TfiI</i>	present study
Coding region	Gly272Asp	GGT 815 GAT	HT1A-HF HT1A-HR	8% PAG (49:1, A:B ratio) 10% glycerol	<i>FokI</i>	present study
	Pro16Leu	CCG 47 CTG	HT1A-EF HT1A-ER	10% PAG (99:1, A:B ratio)	<i>MspI</i>	Harada et al., 1996
	294G→A	GTG 294 GTA Val98 (silent)	HT1A-FF HT1A-FR	10% PAG (99:1, A:B ratio)	<i>RsaI</i>	Xie et al., 1995
	549C→T	CCC 549 CCT Pro183 (silent)	HT1A-GF HT1A-GR	10% PAG (49:1, A:B ratio) 10% glycerol	not available	Erdmann et al., 1995

PAG, polyacrylamide gel; A:B ratio, acrylamide:bisacrylamide ratio.

TABLE 5. Genotype and allele frequencies of the 5-HT_{1A} receptor gene variants in schizophrenic patients and controls

Samples	Genotype distribution											
	Pro16Leu			294G→A			549C→T			Gly272Asp		
	Pro/Pro	Pro/Leu	Leu/Leu	G/G	G/A	A/A	C/C	C/T	T/T	Gly/Gly	Gly/Asp	Asp/Asp
Schizophrenia n=61	58 (95.1%)	3 (4.9%)	0 (0%)	59 (96.7%)	2 (3.3%)	0 (0.0%)	59 (96.7%)	2 (3.3%)	0 (0%)	55 (90.2%)	5 (8.2%)	1 (1.6%)
Control n=100	92 (92.0%)	8 (8.0%)	0 (0%)	91 (91.0%)	9 (9.0%)	0 (0.0%)	93 (93.0%)	7 (7.0%)	0 (0%)	95 (95.0%)	5 (5.0%)	0 (0%)
P value*	P=0.5360			P=0.2091			P=0.4847			P=0.3347		
OR	0.595 [0.152-2.335]			0.343 [0.072-1.643]			0.450 [0.090-2.243]			2.073 [0.604-7.111]		
	Allele frequency											
	Pro16	Leu16	294G	294A	549C	549T	Gly272	Asp272				
	Schizophrenia n=61	0.975	0.025	0.984	0.016	0.984	0.016	0.943	0.057			
Control n=100	0.960	0.040	0.955	0.045	0.965	0.035	0.975	0.025				
P value*	P=0.5433		P=0.2173		P=0.4913		P=0.2231					
OR	0.605 [0.157-2.326]		0.354 [0.075-1.666]		0.460 [0.094-2.250]		2.374 [0.736-7.655]					

*P values were calculated by Fisher's exact test. OR, odds ratio; 95% confidence intervals are given in square brackets.

TABLE 6. Detection of DNA sequence variants in the promoter region of the human AP-2 gene

Nucleotide change	Primer set	Gel condition for SSCP analysis	Restriction enzyme
-1769G→A	AP2PUF AP2PUR	7% PAG (49:1, A:B ratio)	not available
-803G→T	AP2PMF AP2PMR	7% PAG (49:1, A:B ratio)	not available
-90G→C	AP2STRPF AP2STRPR	10% PAG (99:1, A:B ratio)	<i>Msp</i> I

PAG, polyacrylamide gel; A:B ratio, acrylamide:bisacrylamide ratio.

TABLE 7. Polymorphic status between the -90 and -803 loci of the AP-2 gene in schizophrenics (a) and controls (b)

a)

-90 \ -803	GG	GC	CC	total
GG	35	1	0	36
GT	0	38	1	39
TT	0	0	12	12
total	35	39	13	87

(delta value=0.2268, $\chi^2=157.259$, df=1, P<0.000001)

b)

-90 \ -803	GG	GC	CC	total
GG	43	1	0	44
GT	0	49	0	49
TT	0	1	6	7
total	43	51	6	100

(delta value=0.2107, $\chi^2=159.198$, df=1, P<0.000001)

TABLE 8. Genotype and allele frequencies at the -90 and -803 loci of the AP-2 gene in schizophrenics including subtypes and course specifiers, and controls.

Subjects (numbers)	-90 locus					-803 locus				
	Genotypes			Alleles		Genotypes			Alleles	
	GG (%)	GC (%)	CC (%)	G (%)	C (%)	GG (%)	GT (%)	TT (%)	G (%)	T (%)
Schizophrenics (87)	35 (40)	39 (45)	13 (15)	109 (63)	65 (37)	36 (41)	39 (45)	12 (14)	111 (64)	63 (36)
	$\chi^2=4.12, P=0.128$			P=0.275		$\chi^2=2.36, P=0.307$			P=0.381	
Paranoid type (18)	11 (61)	5 (28)	2 (11)	27 (75)	9 (25)	11 (61)	5 (28)	2 (11)	27 (75)	9 (25)
	$\chi^2=3.41, P=0.181$			P=0.556		$\chi^2=2.80, P=0.247$			P=0.556	
Disorganized type (28)	7 (25)	16 (57)	5 (18)	30 (54)	26 (46)	7 (25)	16 (57)	5 (18)	30 (54)	26 (46)
Subtypes	$\chi^2=5.55, P=0.062$			P=0.056		$\chi^2=5.02, P=0.081$			P=0.056	
Catatonic type & Undifferentiated type (13)	5 (39)	6 (46)	2 (15)	16 (62)	10 (38)	6 (46)	5 (39)	2 (15)	17 (65)	9 (35)
	$\chi^2=1.54, P=0.463$			P=0.507		$\chi^2=1.30, P=0.523$			P=0.824	
Residual type (28)	12 (43)	12 (43)	4 (14)	36 (64)	20 (36)	12 (43)	13 (46)	3 (11)	37 (66)	19 (34)
	$\chi^2=2.22, P=0.330$			P=0.628		$\chi^2=0.423, P=0.810$			P=0.748	
Episodic (53)	21 (39)	20 (38)	12 (23)	62 (58)	44 (42)	22 (41)	20 (38)	11 (21)	64 (60)	42 (40)
	$\chi^2=9.56, P=0.008^1$			P=0.101		$\chi^2=6.60, P=0.037^2$			P=0.166	
Continuous (19)	7 (37)	12 (63)	0 (0)	26 (68)	12 (32)	7 (37)	12 (63)	0 (0)	26 (68)	12 (32)
Course	$\chi^2=1.73, P=0.421$			P=1.000		$\chi^2=2.15, P=0.342$			P=1.000	
Single episode & Other or unspecified pattern (15)	7 (47)	7 (47)	1 (6)	21 (70)	9 (30)	7 (47)	7 (47)	1 (6)	21 (70)	9 (30)
	$\chi^2=0.098, P=0.952$			P=1.000		$\chi^2=0.038, P=0.981$			P=1.000	
Controls (100)	43 (43)	51 (51)	6 (6)	137 (69)	63 (31)	44 (44)	49 (49)	7 (7)	137 (69)	63 (31)

P values after the Bonferroni correction were ¹ P=0.064, ² P=0.296.

TABLE 9. Condition for detection of DNA sequence variants in the promoter region of the human CREB gene, and genotype distribution and allele frequency

Nucleotide change	-933T→C			-413G→A		
Primer set	CREB-UF CREB-UR			CREB-MF CREB-MR		
Gel condition for SSCP analysis	7% PAG (49:1, A:B ratio) 10% glycerol			7% PAG (49:1, A:B ratio) 10% glycerol		
Restriction enzyme	not available			<i>Hph</i> I		
	Genotype distribution					
	T/T	T/C	C/C	G/G	G/A	A/A
Schizophrenia n=80	79 (98.8%)	1 (1.2%)	0 (0%)	79 (98.8%)	1 (1.2%)	0 (0%)
Control n=100	100 (100%)	0 (0%)	0 (0%)	100 (100%)	0 (0%)	0 (0%)
P value	P=0.44			P=0.44		
	Allele frequency					
	-933T	-933C		-413G		-413A
Schizophrenia n=80	0.994	0.006		0.994		0.006
Control n=100	1.000	0		1.000		0
P value	P=1.00			P=1.00		

P values were calculated by Fisher's exact test.

PAG, polyacrylamide gel; A:B ratio, acrylamide:bisacrylamide ratio.

TABLE 10. Clinical characteristics of schizophrenic patients possessing the variants in the promoter region of the human CREB gene

Variant	-933T→C	-413G→A
Age	24	40
Age at onset	13	15
Sex	Female	Male
Family history	Uncle	None
Subtype	Undifferentiated type	Disorganized type
Longitudinal course	Episodic with interepisode residual symptoms	Continuous with prominent negative symptoms
Characteristic symptoms	<ul style="list-style-type: none"> •Auditory hallucinations •Persecutory delusions •Visual hallucinations •Conversion symptoms •Intellectual impairment (IQ 54 by WAIS-R testing) 	<ul style="list-style-type: none"> •Auditory hallucinations •Passivity experiences •Disorganized speech •Affective flattening
EEG	slow wave abnormal	within normal limits
CT	within normal limits	not performed
MRI	within normal limits	not performed
Neurological examination	within normal limits	within normal limits